OR WAIT null SECS
October 24, 2019
The transaction is set to be completed in the first quarter of 2020.
Through the agreement, Foamix will have access to $20 million of financing to fund the commercial launches of the topical treatments.
October 22, 2019
The transaction is anticipated to close by the end of 2019.
October 17, 2019
A complete understanding of primary packaging physicochemical properties is necessary in the formulation and development of biologics.
Orgenesis has signed a co-development agreement with Accelix to integrate advanced optic technologies, cartridges, and software onto POCare platform.
GammaDelta Therapeutics has unveiled the formation of a new spin-out company, Adaptate Biotherapeutics, aimed at developing antibody-based therapies that modulate gamma delta T-cells.
Enterprise Therapeutics is the recipient of funding worth up to £5.7 million (US $7 million) from the Cystic Fibrosis Foundation.
October 16, 2019
The long-term agreement gives CombiGene the authority to manufacture and commercialize the drug if it is approved after clinical studies.
The transaction gives Alexion access to Achillion’s portfolio of oral small-molecule Factor D inhibitors to treat people with complement alternative pathway-mediated rare diseases.
October 15, 2019
Lonza, through its Ibex Solutions, will now cover preclinical and clinical development and manufacturing for a significant portion of Genmab’s pipeline.